ValiRx Share News (VAL)
VAL Share
VAL Share
VAL Share
VAL Share
VAL
VAL Share
VAL Level 2
VAL Live
VAL Broker
VAL Directors
VAL Financial
VAL
VAL Short
VAL
Last checked at -
Mon, 06th Jul 2020 18:19
ValiRx PLC - London-based clinical stage biotechnology company - Lays out strategy to build on portfolio of drug candidates in the oncology and women's health space. "The company plans to apply both intellectual and financial resources to each project and enable acceleration through pre-clinical development," ValiRx said.
Current stock price: 8.12 pence
Year-to-date change: down 46%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
(ShareCast News) - Lifesciences company ValiRx reported on a "significant year" on Thursday, talking up its capital restructure and technical advancements in the 2015 calendar year. The AIM-traded firm, which focuses on cancer therapeutics and diagnostics for personalised medicine, said its Phase I/
Read more(ShareCast News) - ValiRx was pressing ahead with the trial process for its VAL201 trial treatment on Tuesday, following positive results from the most recent tranche of test patients. The AIM-traded life science company, with a focus on cancer diagnostics and therapeutics for personalised medicine,
Read more(ShareCast News) - ValiRx was confident in the potential of two of its compounds on Tuesday, in its quarterly update on its ongoing clinical trials. The AIM-traded life science firm, with a focus on cancer diagnostics and therapeutics for personalised medicine, said that recent testing had shown VAL
Read more
Last checked at